The Lyme Wars: time to listen.
Lyme disease represents a public health threat of major proportions. The murky science and acrimonious politics of Lyme disease have created barriers to reliable diagnosis and effective treatment of this protean illness. Two major clinical problems with the disease are the absence of a therapeutic end point in treating Borrelia burgdorferi, the spirochetal agent of Lyme disease, and the presence of tick-borne co-infections, such as babesiosis, anaplasmosis and bartonellosis, that may complicate the course of the illness. From a pathophysiological standpoint, the affinity of B. burgdorferi for multiple cell types and the presence of non-replicating forms of the spirochete have contributed to persistent infection and failure of simple antibiotic regimens. Newer approaches to the treatment of Lyme disease should take into account its clinical complexity in co-infected patients and the possible need for prolonged combination therapy in patients with persistent symptoms of this potentially debilitating illness. The risk and prevention of human transmission of Lyme disease merit further study.
D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use; D015748:Borrelia burgdorferi Group / Q000187:drug effects; D004195:Disease Models, Animal; D018562:Disease Transmission, Infectious; D004318:Doxycycline / Q000008:administration & dosage / Q000627:therapeutic use; D004351:Drug Resistance; D006801:Humans; D008193:Lyme Disease / Q000517:prevention & control / Q000628:therapy / Q000635:transmission; D022123:Lyme Disease Vaccines
D000900:Anti-Bacterial Agents; D022123:Lyme Disease Vaccines; D004318:Doxycycline